Viswanathan Muthusamy
Affiliations: | 2008- | Yale University, New Haven, CT |
Google:
"Viswanathan Muthusamy"Mean distance: 8.42 | S | N | B | C | P |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Caianiello DF, Zhang M, Ray JD, et al. (2021) Bifunctional small molecules that mediate the degradation of extracellular proteins. Nature Chemical Biology |
Jiang X, Muthusamy V, Fedorova O, et al. (2019) Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. The Journal of Experimental Medicine |
Chirkin E, Muthusamy V, Mann P, et al. (2017) Neutralization of pathogenic fungi with small-molecule immunotherapeutics. Angewandte Chemie (International Ed. in English) |
Micevic G, Muthusamy V, Damsky W, et al. (2016) DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports |
Rullo AF, Fitzgerald KJ, Muthusamy V, et al. (2016) Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie (International Ed. in English) |
Muthusamy V, Premi S, Soper C, et al. (2013) The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma. The Journal of Investigative Dermatology. 133: 1827-33 |
Smalley KS, Contractor R, Nguyen TK, et al. (2008) Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Research. 68: 5743-52 |
Muthusamy V, Duraisamy S, Bradbury CM, et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Research. 66: 11187-93 |